Stock 6634 SINEW PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinew Pharma Inc.

Equities

6634

TW0006634009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
55.3 TWD -1.25% Intraday chart for Sinew Pharma Inc. -2.47% -18.32%
03-19 Sinew Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Sinew Pharma Inc.(TPEX:6634) added to S&P Global BMI Index CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 530.2 965.7 4,753 5,659 7,326 4,798
Enterprise Value (EV) 1 407.2 678.1 4,418 4,177 5,942 3,532
P/E ratio -7.12 x -12.6 x -55.5 x -53.2 x -51.9 x -27.9 x
Yield - - - - - -
Capitalization / Revenue - - 10,288,798,701 x 908,447,183 x 22,335,548,780 x -
EV / Revenue - - 9,563,748,918 x 670,590,705 x 18,117,189,024 x -
EV / EBITDA -6.87 x -11.3 x -68.6 x -56.5 x -46.3 x -21.6 x
EV / FCF -13.8 x 3.42 x -16.7 x -122 x -115 x -49.1 x
FCF Yield -7.27% 29.3% -5.99% -0.82% -0.87% -2.04%
Price to Book 2.21 x 5.72 x 11 x 3.61 x 5.02 x 3.64 x
Nbr of stocks (in thousands) 38,170 38,320 51,950 69,009 69,772 70,871
Reference price 2 13.89 25.20 91.50 82.00 105.0 67.70
Announcement Date 03/04/19 30/03/20 26/03/21 21/03/22 22/03/23 19/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - 0.462 6.229 0.328 -
EBITDA 1 -59.31 -59.88 -64.41 -73.88 -128.3 -163.6
EBIT 1 -75.9 -76.84 -84.11 -94.42 -148.4 -186.3
Operating Margin - - -18,204.76% -1,515.81% -45,252.44% -
Earnings before Tax (EBT) 1 -74.47 -76.22 -82.01 -91.58 -140.2 -170.9
Net income 1 -74.47 -76.22 -82.01 -91.58 -140.2 -170.9
Net margin - - -17,751.3% -1,470.14% -42,737.8% -
EPS 2 -1.951 -1.993 -1.650 -1.540 -2.023 -2.430
Free Cash Flow 1 -29.58 198.4 -264.7 -34.31 -51.5 -71.93
FCF margin - - -57,288.64% -550.85% -15,701.03% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 03/04/19 30/03/20 26/03/21 21/03/22 22/03/23 19/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 123 288 335 1,482 1,384 1,266
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -29.6 198 -265 -34.3 -51.5 -71.9
ROE (net income / shareholders' equity) -26.9% -37.3% -27.1% -9.14% -9.26% -12.3%
ROA (Net income/ Total Assets) -16.5% -14.3% -12% -5.79% -6.04% -8.17%
Assets 1 451.2 534.1 681.7 1,581 2,321 2,093
Book Value Per Share 2 6.290 4.400 8.330 22.70 20.90 18.60
Cash Flow per Share 2 1.090 6.590 0.9000 7.990 3.540 2.340
Capex 1 0.45 5.28 1.8 2.18 5.23 7.21
Capex / Sales - - 389.39% 35.03% 1,592.99% -
Announcement Date 03/04/19 30/03/20 26/03/21 21/03/22 22/03/23 19/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SINEW PHARMA INC. Stock Sinew Pharma Inc.
-18.32% 121M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6634 Stock
  4. Financials Sinew Pharma Inc.